ERBB2 and breast cancer: First-line treatment is usually represented by endocrine therapy (e.g., aromatase inhibitors and fulvestrant ±CDK 4/6 inhibitors) in case of HR-positive disease and by targeted therapies (e.g., trastuzumab/pertuzumab + chemotherapy) in patients with HER2-positive BC [7].